GlassScriptPhysician profile
Keeshia D Cloud
NPI 1205254588
$2,176.85
in general payments reported to CMS, 2019-2025
23 companies · $374 in 2025
The $374 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $834 · 2022: $479 · 2023: $62.11 · 2024: $428 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $850 · Entertainment: $13.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $849.93 |
| Entertainment | $13.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $470.16 | 2021-2024 | Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $285.35 | 2024-2025 | Relistor, Trulance |
| Optinose US, INC. | $232.13 | 2021-2022 | |
| Glaxosmithkline, LLC. | $218.50 | 2021-2022 | |
| Indivior INC. | $199.24 | 2024-2025 | Sublocade |
| Lilly USA, LLC | $155.55 | 2021-2024 | Mounjaro, Emgality, Jardiance |
| Amarin Pharma, INC. | $125.27 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $97.14 | 2021-2022 | |
| Exact Sciences Corporation | $56.31 | 2024-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.83 | 2024-2025 | Caplyta |
| Pfizer INC. | $39.76 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $38.95 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $25.29 | 2021 | |
| Amgen INC. | $24.13 | 2021 | |
| Atland Pharmaceuticals, LLC | $22.80 | 2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $21.42 | 2025 | Sunosi |
| Protega Pharmaceutials INC | $20.78 | 2025 | Roxybond |
| Dexcom, INC. | $20.00 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $17.04 | 2025 | |
| Lundbeck LLC | $15.24 | 2025 | Vyepti |
| Tolmar, INC. | $14.56 | 2025 | Jatenzo |
| Optos, INC. | $13.78 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Genentech USA, INC. | $13.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keeshia Cloud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.